FDA Will Seriously Consider Concerta Petition, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will seriously consider Johnson & Johnson's citizen petition filed in an effort to block approval of generic Concerta, the company says
You may also be interested in...
Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party
In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.
Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party
In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.
Andrx Expects “Near Term” FDA Response To Petition Blocking Concerta Generics
McNeil’s citizen petition requests FDA apply additional bioequivalence requirements for Concerta ANDAs. With no patent exclusivity remaining on the innovator product, multiple generics could be approved if FDA rejects McNeil’s arguments.